Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway

Detalles Bibliográficos
Autores principales: Guo, Ruixue, Wang, Peipei, Zheng, Xuejun, Cui, Wen, Shang, Jin, Zhao, Zhanzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815602/
https://www.ncbi.nlm.nih.gov/pubmed/36618948
http://dx.doi.org/10.3389/fphar.2022.1074294
_version_ 1784864357108154368
author Guo, Ruixue
Wang, Peipei
Zheng, Xuejun
Cui, Wen
Shang, Jin
Zhao, Zhanzheng
author_facet Guo, Ruixue
Wang, Peipei
Zheng, Xuejun
Cui, Wen
Shang, Jin
Zhao, Zhanzheng
author_sort Guo, Ruixue
collection PubMed
description
format Online
Article
Text
id pubmed-9815602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98156022023-01-06 Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway Guo, Ruixue Wang, Peipei Zheng, Xuejun Cui, Wen Shang, Jin Zhao, Zhanzheng Front Pharmacol Pharmacology Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9815602/ /pubmed/36618948 http://dx.doi.org/10.3389/fphar.2022.1074294 Text en Copyright © 2022 Guo, Wang, Zheng, Cui, Shang and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Guo, Ruixue
Wang, Peipei
Zheng, Xuejun
Cui, Wen
Shang, Jin
Zhao, Zhanzheng
Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title_full Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title_fullStr Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title_full_unstemmed Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title_short Corrigendum: SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R/PI3K pathway
title_sort corrigendum: sglt2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the igf1r/pi3k pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815602/
https://www.ncbi.nlm.nih.gov/pubmed/36618948
http://dx.doi.org/10.3389/fphar.2022.1074294
work_keys_str_mv AT guoruixue corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway
AT wangpeipei corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway
AT zhengxuejun corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway
AT cuiwen corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway
AT shangjin corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway
AT zhaozhanzheng corrigendumsglt2inhibitorssuppressepithelialmesenchymaltransitioninpodocytesunderdiabeticconditionsviadownregulatingtheigf1rpi3kpathway

Ejemplares similares